US2013131032A1PendingUtilityA1

Neurotherapeutic treatment for sexual dysfunction

59
Assignee: REVAAX PHARMACEUTICALS LLCPriority: Jun 18, 2001Filed: Jan 25, 2013Published: May 23, 2013
Est. expiryJun 18, 2021(expired)· nominal 20-yr term from priority
Inventors:Gary A. Koppel
A61P 15/10A61K 31/424A61K 31/431A61K 31/545A61K 31/546A61K 31/43A61K 31/5365
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for improving sexual function is described. A mammal suffering from sexual dysfunction or otherwise in need of enhanced sexual function is administered a compound selected from those that are capable of inhibiting the activity of β-lactams, penicillin-binding protein, carboxypeptidase. Such compounds, including particularly β-lactam ring-containing compounds, can be used to formulate pharmaceutical formulations useful for improving sexual function.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for treating a disease characterized by a neurological dysfunction treatable by activation of serotonin or dopamine neurotransmission comprising the step of administering a β-lactam compound capable of inhibiting the activity of a bacterial enzyme selected from β-lactamase or a penicillin binding protein or a carboxypeptidase, where the β-lactam compound is administered in an amount effective to activate serotonin and/or dopamine neurotransmission in the brain, thereby treating the disease characterized by a neurological dysfunction. 
     
     
         2 . The method of  claim 1 , wherein the compound is a β-lactamase inhibitor. 
     
     
         3 . The method of  claim 1 , wherein the compound is a β-lactam antibiotic. 
     
     
         4 . The method of  claim 1 , wherein the compound is clavulanic acid or a pharmaceutically acceptable salt or ester thereof. 
     
     
         5 . The method of  claim 1 , wherein the compound is administered orally. 
     
     
         6 . The method of  claim 1 , wherein the compound is administered sublingually or buccally. 
     
     
         7 . The method of  claim 1 , wherein the compound is administered transdermally. 
     
     
         8 . The method of  claim 1 , wherein the compound is administered parenterally. 
     
     
         9 . The method of  claim 1 , wherein the amount is less than an antibiotically effective amount. 
     
     
         10 . The method of  claim 4 , wherein the amount is less than an antibiotically effective amount. 
     
     
         11 . The method of  claim 1 , wherein the disease characterized by a neurological dysfunction is selected from the group consisting of addiction, obesity, and schizophrenia. 
     
     
         12 . The method of  claim 4 , wherein the ester group selected from the group consisting of an acyloxyalkyl, alkoxycarbonyloxyalkyl, dialkylaminoalkyl, 2-(alkoxycarbonyl)-2-alkenyl, and lactone groups. 
     
     
         13 . The method of  claim 12 , wherein the ester group is selected from the group consisting of acetoxymethyl, pivaloyloxymethyl, β-acetoxyethyl, β-pivaloyloxyethyl, 1-(cyclohexylcarboonyloxy)prop-1-yl, (1-aminoethyl)carbonyloxymethyl, ethoxycarbonyloxymethyl, alpha-ethoxycarbonyloxyethyl, β-ethoxycarbonyloxyethyl, dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl, diethylaminoethyl, 2-(isobutoxycarbonyl)pent-2-enyl, 2-(ethoxycarbonyl)but-2-enyl, phthalidyl and dimethoxyphthalidyl. 
     
     
         14 . The method of  claim 1 , wherein the disease characterized by a neurological dysfunction is treatable by activation of dopamine neurotransmission in the brain. 
     
     
         15 . The method of  claim 4 , wherein the compound is a pharmaceutically acceptable salt of clavulanic acid. 
     
     
         16 . A pharmaceutical composition for treating a disease characterized by a neurological dysfunction treatable by activation of serotonin or dopamine neurotransmission comprising a β-lactam compound in an amount effective to activate serotonin and/or dopamine neurotransmission in the brain and treat the disease characterized by a neurological dysfunction. 
     
     
         17 . The pharmaceutical composition of  claim 16 , wherein the compound is clavulanic acid or a pharmaceutically acceptable salt or ester thereof. 
     
     
         18 . The pharmaceutical composition of  claim 16 , wherein the composition is suitable for oral administration. 
     
     
         19 . The pharmaceutical composition of  claim 17 , wherein the compound is a pharmaceutically acceptable salt of clavulanic acid.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.